Pharmos Corp. began dosing in a second Phase IIa study of cannabinor (PRS-211,375) for the treatment of pain. The proof-of-concept trial will test for analgesic activity and safety in healthy subjects experiencing capsaicin-induced pain. The study will include 24 male subjects in a two-way crossover design and is expected to be complete in the fourth quarter of this year. In addition to the ongoing clinical testing of cannabinor in an intravenous formulation, Pharmos is developing an oral fo...